Latest Immuno Oncology News

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.

Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR incorporated into iNKT cells effectively eliminates pancreatic and gastric cancer cells in vitro, with IL-12-TM armouring enhancing potency and durability.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

Imugene has secured FDA backing to advance its allogeneic CAR T therapy, azer-cel, into a pivotal Phase 3 trial targeting difficult-to-treat diffuse large B-cell lymphoma (DLBCL), including patients relapsed after prior CAR-T treatment.

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.